

Princeton / Somerset New Jersey
 49 Veronica Avenue
 Suite 202
 Somerset, NJ 08873



Canakinumab (Ilaris)
 Provider Order Form

Date: _____

| PATIENT INFORMATION | | |
|--|---------------------|--|
| Name: | DOB: | SEX: M <input type="checkbox"/> F <input type="checkbox"/> |
| ICD-10 code (required): | ICD-10 description: | |
| <input type="checkbox"/> NKDA Allergies: | Weight lbs/kg: | |

| REFERRAL STATUS |
|---|
| <input type="checkbox"/> New Referral <input type="checkbox"/> Referral Renewal <input type="checkbox"/> Medication/Order Change <input type="checkbox"/> Benefits Verification Only <input type="checkbox"/> Discontinuation Order |

| PHYSICIAN INFORMATION | |
|----------------------------|--|
| Referral Coordinator Name: | Referral Coordinator Email: |
| Ordering Provider: | Provider NPI: |
| Referring Practice Name: | Phone: _____ Fax: _____ |
| Practice Address: | City: _____ State: _____ Zip Code: _____ |

OBSERVATION (PLEASE SELECT BELOW)

Patient is required to stay for 30 minutes observation period
 Patient is NOT required to stay for observation time
 Other: _____

SPECIAL INSTRUCTIONS

THERAPY ADMINISTRATION

Canakinumab (Ilaris)

For Stills Disease including Adult Onset Stills Disease and Systemic Juvenile Idiopathic Arthritis.

4mg/kg (with a max of 300mg) for patients with a body weight greater than or equal to 7.5kg subcutaneous every 4 weeks
 Other _____

For Cryopyrin-Associated Periodic Syndromes (CAPS)

150mg for patients with body weight greater than 40kg subcutaneous every 8 weeks

 2mg/kg for patients with body weight greater than or equal to 15kg and less than or equal to 40kg subcutaneous every 8 wks
 Other _____

For Tumor Necrosis Factor Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency, Familial Mediterranean Fever

Body weight less than or equal to 40kg

2mg/kg subcutaneous every 4 weeks
 4mg/kg subcutaneous every 4 weeks - consider if clinical response not adequate. Other _____

Body weight greater than 40kg

150mg subcutaneous every 4 weeks
 300mg subcutaneous every 4 weeks - consider if clinical response not adequate.

Refills: Zero / for 12 months / _____ (if not indicated order will expire one year from date signed) Other _____

Total Doses _____ Refills _____

NOTES/ADDITIONAL COMMENTS:

ORDERING PROVIDER

Signature X _____ Date _____

Provider _____ Phone _____ Fax _____